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the CC BY-NC-ND license (http://creaAbstract The clinical development of immunotherapy has gained significant impetus in
recent years across the field of medical oncology. Mounting preclinical and clinical data have
demonstrated the potential of immune-based treatments to augment anti-tumor immune
responses. With one of the first modern immunotherapies approved in prostate cancer and
multiple others in late stage development, immune treatment strategies need to be optimized
to ensure the best clinical outcomes. Combination strategies with androgen deprivation
therapy, anti-androgen therapy, radiation and chemotherapy have demonstrated the potential
maximize immune response in prostate cancer patients. These combinations are currently
being evaluated in clinical trials at every stage of prostate cancer from the newly diagnosed
to the most advanced stages. Data from these studies will provide guidance for the future
clinical implementation of immunotherapy in prostate cancer.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Amid the significant excitement surrounding immunotherapy
currently being developed for many types of cancer, it is
easy to forget that the first immunotherapy developed as
part of this immunoncology revolution was sipuleucel-T
for prostate cancer in 2010 [1]. While much of the current
focus of immunotherapy development is focused on immunegov (R.A. Madan).
of Second Military Medical
.08.008
sian Journal of Urology. Producti
tivecommons.org/licenses/by-nc-checkpoint inhibitors, therapeutic cancer vaccines have less
toxicity and may provide a means by which the efficacy of
immune checkpoint inhibitors could be optimized [2].
Emerging preclinical and clinical data suggest that vaccines
can also be combined with standard therapies such as
chemotherapy, radiopharmaceuticals, and anti-androgen
therapy based on synergistic properties of immuneactivation.
2. Clinical development of immunotherapy in
prostate cancer
Sipuleucel-T is a therapeutic cancer vaccine that targets
prostatic acid phosphatase (PAP) and has been approved byon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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the treatment of metastatic castration resistant
prostate cancer (mCRPC) [1,3] (Table 1). This treatment is
generated from a patient’s own immune cells which are
processed ex vivo at a central processing facility. The
process is initiated when patients have their peripheral
blood immune cells extracted from circulation via
apheresis. The immune cells are then shipped to the
central processing facility where they are exposed to the
target antigen PAP and granulocyte e monocyte colony
stimulating factor over a 48 h period [3]. Once the
processing is complete, immune release criteria are
confirmed based on CD54 expression [4]. Immune cells are
then shipped back to the patient’s infusion center where
they are re-infused into the patient’s circulation. A full
course of therapy consists of three infusions done every 2
weeks over the course of one month. Preliminary phase 1
studies with this therapy demonstrated that the strategy
was well tolerated with limited toxicity include infusion
reactions and transient flu associated symptoms [3].
The phase 3 study enrolled 512 patients with mCRPC and
randomly assigned patients in a 2:1 fashion to either
sipuleucel-T or placebo [1]. The findings of the study
demonstrated a 22% reduction in the risk of death for
patients randomly assigned to treatment with sipuleucel-T
(hazard ratio (HR), 0.78; 95% confidence interval (CI),
0.61 to 0.98; pZ 0.03). In association with that finding was
a median improvement in survival of 25.8 months in the
sipuleucel-T arm of the study compared to 21.7 months in
the patients treated with placebo. The treatment was again
well tolerated similar to the phase 1 studies with transient
fevers, chills and headache representing the most
commonly observed toxicity. A recent analysis of the
placebo arm of this trial suggests that a salvage therapy
given as part of a planned cross-over in the definitive phase
3 trial resulted in survival times that were longer than
expected in that group [5]. If that interpretation is
accurate, the survival effect of sipuleucel-T in mCRPC may
actually be underestimated in this study.Table 1 Key trial results of Sipuleucel-T in prostate cancer.
Ref. Trial and population Patients (n)
Kantoff
et al. [1]
Phase 3 trial in metastatic
castration resistant prostate
cancer
512
Schellhammer
et al. [13]
Phase 3 trial in metastatic
castration resistant prostate
cancer
512
Fong et al. [9] A phase 2 study using sipuleucel-T
in the neoadjuvant setting before
radical prostatectomy
42
PSA, prostate specific antigen.The most controversial finding of the study was the fact
that disease progression was equivalent in both arms of the
study. Although such findings are more commonly observed
in immunotherapy trials since the publication of these
results, this apparent paradox between improved survival
despite lack of change in (short-term) progression free
survival was relatively unique at that time [6]. Indeed this
was not the first time this apparent discrepancy was
observed. An earlier phase 3 trial evaluating sipuleucel-T
which enrolled 125 patients, but demonstrated no
difference between progression free survival despite an
improved overall survival advantage (a benefit that was
similar to the larger phase 3 trial) [1,7]. In fact, it was the
findings of this initial phase 3 trial that led to the redesign
and initiation of a subsequent phase 3 trial with overall
survival as an endpoint. It is also worth noting that the
same phenomenon (improved survival without a change in
short-term progression) was observed in the metastatic
melanoma trials with ipilimumab which led to its FDA
approval and wide use [8]. Despite the apparent
consistency between these two studies involving
sipuleucel-T and the study of immunotherapy in melanoma,
there was significant skepticism about the efficacy of
sipuleucel-T and its true therapeutic benefit in men with
advanced prostate cancer. Despite the randomized data
and growing support for immunotherapy in general, much
of this uncertainty remains to this day, limiting the number
of patients who are actually treated with sipuleucel-T.
A subsequent clinical trial involving sipuleucel-T in the
neoadjuvant setting has potentially provided immunologic
mechanism of action data which has substantially
contributed to the understanding of how sipuleucel-T may
induce immune responses in patients with prostate cancer
[9]. This trial enrolled men who are candidates for
definitive radical prostatectomy to treat newly diagnosed
prostate cancer. Patients were given neoadjuvant
sipuleucel-T and then the prostate tissue was evaluated
after surgical resection. The results suggested a greater
than three-fold increase in infiltrating T cells at the benignSummary of key findings
Demonstrated an improvement in overall survival of 25.8
months in the sipuleucel-T arm of the study compared to
21.7 months in the placebo arm (hazard ratio, 0.78; 95%
confidence interval, 0.61 to 0.98; p Z 0.03)
A retrospective analysis suggested that patients with a PSA
less than or equal to 22.1 ng/mL had a 62.6% three-year
estimated survival after treatment with sipuleucel-T
compared to 41.6% in the placebo group. These data suggest
that patients with lower tumor volume may benefit most
from sipuleucel-T
The study found a greater than three-fold increase in
infiltrating T cells at the benign tissue-tumor interface
within the prostate (p < 0.001) after treatment with
sipuleucel-T compared to pre-treatment biopsies. This
study suggested that sipuleucel-T can mobilize T cells to the
tumor microenvironment
280 J.L. Gulley, R.A. Madantissueetumor interface within the prostate (p < 0.001)
after treatment with sipuleucel-T compared to
pre-treatment biopsies. These findings after radical
prostatectomy were not seen in the control group of 12
untreated patients that were used for comparison. These
findings suggest that sipuleucel-T activated immune cells
and ultimately drove them to the primary tumor and its
microenvironment.
Developing immune checkpoint inhibitors in prostate
cancer has also been explored in mCRPC. Ipilimumab is an
antibody targeting cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4), a checkpoint molecule expressed by
activated T cells. Blocking this molecule has been shown to
mitigate auto-regulation by the immune system, lead to
both autoimmune and anti-cancer effects [10]. This agent
has demonstrated the ability to improve survival (also
without a progression free survival benefit) in metastatic
melanoma [8]. Ipilimumab has been evaluated in two
phase 3 trials in mCRPC, involving patients who were both
chemotherapy-naı¨ve and those who had been previously
treated with chemotherapy. The trial in the most
advanced population, those had previously been treated
with docetaxel, randomized patients to either placebo or
ipilimumab included radiation [11]. All patients were also
treated with low dose radiation to a limited number of
metastatic bone lesions. This was not done for therapeutic
purposes, but rather as an immune adjuvant based on
preliminary data that suggested that such radiation could
be combined with ipilimumab to enhance the immune
responses [12]. Despite a trend to improved outcomes in
patients treated with ipilimumab, the trial failed to meet
its primary endpoint of overall survival (median overall
survival of 11.2 months in the ipilimumab arm compared to
10 months in the control arm; HR, 0.85, 95% CI, 0.72e1.00;
p Z 0.053) [11]. To this point the trial in chemotherapy-
naı¨ve patients (NCT01057810), which randomized patients
to either placebo or ipilimumab (without radiation) has not
reported a survival benefit either. Therefore the role of
immune checkpoint inhibitors as monotherapy in prostate
cancer remains undefined.3. Who should be treated with immunotherapy
in prostate cancer?
Identifying the appropriate patients who could benefit from
immunotherapy remains a challenge in medical oncology.
Retrospective data in prostate cancer, however, suggest
that patients with relatively less tumor burden and more
indolent disease characteristics are more likely to have
improved clinical outcomes after being treated with
immunotherapy. These data provide some degree of clinical
instruction for the use of sipuleucel-T in prostate cancer
and also provide guidance in the development of new
clinical trials investigating immunotherapy for prostate
cancer.
Although there are many caveats about the use of
prostate specific antigen (PSA) given interpatient
variability, a retrospective analysis of the registration
phase 3 trial for sipuleucel-T suggests that patients with a
lower PSA derive the greatest benefit from treatment with
the therapeutic cancer vaccine [13]. Of the 512 patientsenrolled in the study, the quartile of patients which
had the lowest PSA had values less than or equal to
22.1 ng/mL. The overall survival HR for these patients was
0.51 (95% CI, 0.31e0.85) and substantially better than the
patients in the highest quartile, whose PSA values were
greater than 134 ng/mL (HR, 0.84; 95% CI, 0.55e1.29).
This analysis suggested that patients with a PSA less than
or equal to 22.1 ng/mL had a 62.6% 3-year estimated
survival after treatment with sipuleucel-T which
demonstrated a substantial improvement compared to
patients randomized to the control arm of the study
(3-year survival was 41.6%). Despite the fact that PSA is
not a perfect surrogate for tumor burden, these data
suggest that patients with relatively lower tumor burdens
are perhaps most appropriate for treatment with
immunotherapy relative to patients with higher volume
disease.
Similar findings were seen in a prespecified analysis of
the ipilimumab trial in mCRPC that enrolled patients who
have already been treated with docetaxel [11]. Although
the study failed to meet its primary endpoint of overall
survival (median overall survival of 11.2 months in the
ipilimumab arm vs. 10 months in the control arm; HR, 0.85,
95% CI, 0.72e1.00; pZ 0.053), there was a suggestion that
patients with more favorable or indolent disease
characteristics had a better clinical response to the
ipilimumab and protocol-specified radiation to bone
metastases relative to the control arm of the study.
Patients receiving ipilimumab (n Z 146) that had an
alkaline phosphatase less than 1.5 times the upper limit of
normal, a hemoglobin concentration greater than 110 g/L in
the absence of visceral metastases had improved overall
survival relative to patients with the same characteristics
who were treated with placebo (n Z 142). The median
survival in this subgroup was 22.7 months compared to 15.8
months (HR, 0.62, 95%CI, 0.45e0.86; pZ 0.0038), favoring
patients treated with ipilimumab.
The findings demonstrated in these two phase 3 trial
subgroup analyses was also seen in an earlier phase 2 trial
with the pox viral based therapeutic cancer vaccine
prostvac in mCRPC. A single arm phase 2 study of 32
patients evaluated patients who had a predicted survival of
greater than 18 months and compared them to patients
who had a predicted survival of less than 18 months using a
contemporary and established predictive nomogram
for mCRPC patients [14]. The findings of the study
suggested that patients with a longer predicted survival had
a median survival of greater than 37.3 months relative to a
predicted survival of 20.9 months. For patients with a
shorter predict survival of less than 18 months, after
treatment with vaccine the median survival was
14.6 months compared to a median predicted survival of
12.3 months.
The combined data from these three trials does not
provide rigid guidelines for who should be treated with
immunotherapy in advanced prostate cancer, but they do
provide a rationale to treat patients with relatively
indolent disease characteristics or lower tumor burden with
immunotherapy. While this cannot guarantee clinical
benefit, it may provide appropriate clinical guidance for
which patients are likely to benefit from such therapies.
Also these data provide the basis for future clinical trial
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characteristics.
4. Immunotherapy combination strategies
4.1. Androgen deprivation therapy
Although sipuleucel-T has demonstrated independent abil-
ity to extend survival in patients with advanced prostate
cancer, there is a substantial amount of preclinical data
suggesting potential immunologic synergy between other
standard therapies in prostate cancer and immunotherapy.
One example is androgen deprivation therapy which is the
cornerstone of therapy for patients with metastatic disease
[15]. Androgen deprivation therapy is also used in patients
with intermediate or high risk disease who are treated with
definitive radiation, and patients with biochemical
recurrent disease who are unsuccessfully treated with
definitive radiation or surgery and then develop recurrent
disease which is only detected by elevated PSA levels.
Preclinical data have suggested that androgen deprivation
therapy can induce T cell migration to the prostate,
decrease immune tolerance for self antigens, and lead to
the increase of naı¨ve T cells produced from the thymus
[16e18]. These findings provide the rationale for combining
immunotherapy with androgen deprivation therapy in
prostate cancer.
A previous clinical trial has demonstrated the ability for
androgen deprivation therapy to increase the production of
naı¨ve T cells from thymus in humans, corroborating the
findings in preclinical models [18,19]. In this trial [18]
patients were given a 3-month depot dose of a
Gonadotropin-releasing hormone (GnRH) agonist, and were
evaluated for both naı¨ve T cell production as well as
changes in T cell receptor excision circles (TRECS). The
latter are the byproduct of T cell receptor gene
rearrangement that occurs when naı¨ve T cells are produced
from the thymus, thereby providing an indirect measure of
thymic activity. In this trial naı¨ve T cells were found to
increase from 3.25% of CD3þ T cells to 3.95% of CD3þ T cells
(p Z 0.0060). In addition, TRECs increased from 93 per
100,000 cells to 147 per 100,000 cells (p Z 0.0025).
These naı¨ve T cells could enhance immune responses
independently or, when androgen deprivation therapy is
combined with immunotherapy, these new T cells could be
activated and have enhanced immune targeting of prostate
cancer cells.
Another trial evaluated sipuleucel-T in combination with
androgen deprivation therapy. The study was designed to
evaluate the optimal scheduling of a therapeutic cancer
vaccine in conjunction with androgen deprivation therapy
[20]. Patients were randomized to either sipuleucel-T
followed by 12 months of androgen deprivation therapy or
sipuleucel-T given three months after androgen deprivation
therapy was initiated and continued for a total of 12 months.
The findings suggested that optimal immune responses were
seen when sipuleucel-Twas given after androgen deprivation
therapy as opposed to prior to androgen deprivation therapy.
Relative increases were seen in multiple cytokine subsets as
well as antigen specific immune responses in a group that
received sipuleucel-T after androgen deprivation therapy.This could provide evidence that the naı¨ve T cells induced by
androgen deprivation therapy are being activated by the
vaccine. Ultimately clinical outcomes related to the
immune responses will be required to pursue this
strategy further however, these data do provide further
rationale for combining androgen deprivation therapy with
immunotherapy.
4.2. Anti-androgen therapy
In recent years, substantial improvements have been made
in the treatment of prostate cancer, including the
development of new anti-androgen therapies such as
enzalutamide and abiraterone [21]. Preclinical data have
again suggested that enzalutamide is capable of inducing
naı¨ve T cells from the thymus, similar to androgen
deprivation therapy. Preclinical studies in male C57BL/6
mice demonstrated that after 14 days there were
statistically significant changes in thymic weight and TREC
production [22]. In addition enzalutamide demonstrated
the ability to induce immunogenic modulation of the tumor.
Relative to controls enzalutamide was able to increase
major histocompatibility complex class 1 (MHC1) expression
by five-fold and Fas ligand expression by nearly two-fold.
The former may be critical in helping the immune system
recognize tumor cells while the latter may enable immune
cells to engage and kill cancer cells. These findings were
associated with increased antigen specific immune cell lysis
of prostate cancer cells in vitro.
These results provide the basis for several ongoing clinical
trials combining immunotherapy with enzalutamide. Two of
the studies are combining enzalutamide with therapeutic
cancer vaccine prostvac. One study is enrolling patients in
mCRPC in an effort to determine if prostvac can enhance the
time to progression already seen with enzalutamide alone
(NCT01867333). A second trial combined prostvac with
enzalutamide in a short 3-month course in patients with
biochemically recurrent prostate cancer (NCT01875250).
The latter group consisted of patients who had normal
testosterone levels and therefore allowed for the evaluation
of the immunologic impact of enzalutamide independent of
androgen deprivation therapy. The preliminary findings from
the study suggested that enzalutamide increased naı¨ve Tcell
production as measured by TRECs [23]. Furthermore,
substantial increases in natural killer cells and decreases in
myeloid derived suppressor cells were also seen in these
patients when baseline values were compared to post
treatment assessments. These favorable immunologic
findings not only support immunologic combination therapies
with enzalutamide in prostate cancer, but also provide
hypothesis generating data about the potential use of
enzalutamide as an immune modulator in other cancers that
are not driven by the androgen receptor. The clinical
readouts from these and other trials will also be important in
determining the role of enzalutamide and immunotherapy
combinations in prostate cancer.
4.3. Radiation therapy
There is also strong preclinical and clinical data to support
the role of radiation therapy as a companion treatment for
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years the concept of an abscopal effect has been
described as an enigmatic biologic phenomenon, but the
growing understanding of the antitumor effects of the
immune system has provided better understanding of the
potential etiology of such findings [24]. It now seems likely
that radiation therapy in addition to killing cancer cells at
the focal target may have a broader immunologic
impact leading to responses beyond the radiation field.
And although rare, reports have emerged where
immunotherapy may augment these non-target immuno-
logic effects, such as the findings reported with an immune
checkpoint inhibitor given after radiation in a patient of
melanoma, leading to a clinical response outside of the
radiation field [25].
Preclinical data have suggested that radiation at doses
lower than cytotoxic magnitude may induce immunogenic
modulation of the tumor leading to increased antigen
expression as well as expression of FAS ligand [26,27].
Similar to what was described with androgen deprivation
therapy, enhancing the ability of the immune system to
recognize the tumor as well as engage and kill the tumor
cells may lead to better clinical responses. This may be an
important concept to consider given that radiation does not
likely hit each tumor cell with the maximum radiation dose
intended. The potential role radiation in prostate cancer is
also important for developing treatment strategies.
Radiation can be used to cure patients in early-stage
disease, salvage in patients who have had surgery that
resulted in residual disease being left behind in the
prostate bed, or palliative measures in advance disease. In
addition to external beam radiation, radiopharmaceuticals
are also used in patients with advanced mCRPC.
An earlier study demonstrated the ability of radiation
can be combined safely with a therapeutic cancer vaccine
strategy in newly diagnosed prostate cancer patients. This
trial treated 30 patients, 19 of which received vaccine in
addition to standard radiation therapy while 11 patients
received radiation therapy alone [28]. The vaccine used in
this trial was a pox viral-based vaccine designed to target
PSA. The results indicated that 13 of the 17 evaluable
patients to that vaccine radiation at a greater than
three-fold increase in PSA specific T cells after both
therapies. In patients who did not receive vaccine in
addition to radiation there was no increase in PSA specific
T cells. These data highlight the potential for radiation
to augment immune responses when combined with
immunotherapy.
Another clinical trial in more advanced prostate cancer
combined the therapeutic cancer vaccine prostvac with
samarium 153 in patients with mCRPC [29]. Samarium 153 is
an FDA approved agent which has demonstrated the ability
to provide palliation for men with advanced mCRPC [30].
This study which, also had a control arm consisting of
samarium 153 alone, treated a very advanced population
of patients who already had progressive disease on
docetaxel-based therapy. The results of the study indicated
that patients who receive the combination of samarium 153
and vaccine (nZ 21) had a greater progression free survival
relative to those who received samarium 153 alone
(n Z 18). The median progression free survival times
were 3.7 months vs. 1.7 months respectively (p Z 0.041,HR, 0.51). In addition, all of patients who had PSA declines
greater than 30% (n Z 4, three of which were greater than
50%) were in the samarium 153 with vaccine treatment arm
of study [29].
Although findings are interesting, they take on a greater
degree of clinical relevance given the approval of radium
223 based on a phase 3 trial that demonstrated its ability to
improve overall survival in patients with mCRPC [31]. In
addition to having the potential ability to extend survival,
radium 223 is much less toxic to the bone marrow than
samarium 153, perhaps allowing it to be used in earlier
stages of disease. Building on this data with samarium 153
and vaccine, there is an ongoing trial which is investigating
the combination of sipuleucel-T with radium 223 in mCRPC
(NCT02463799).
4.4. Chemotherapy
Although oncologists are well versed in the consequences of
immune suppression using chemotherapy, it is now clear
that there are many chemotherapies that actually have a
positive impact on the immune system and its ability to
mount an anti-tumor immune response. Docetaxel has
demonstrated the ability to improve survival at several
stages of prostate cancer [32,33]. In the most advanced
stages of prostate cancer, metastatic castration resistant
disease, it improves overall survival and provides
substantial relief of symptoms. In recent years, the
potential of docetaxel in earlier stages of disease have also
been unveiled. Docetaxel for six cycles has demonstrated
the ability to substantially improve survival in men with
newly diagnosed (castration sensitive disease) when
combined with androgen deprivation therapy compared to
androgen deprivation therapy alone (57.6 vs. 44.0 months;
HR, 0.61; p < 0.001) [34]. In addition, a study that
administered docetaxel after radiation therapy as part of a
definitive treatment strategy for high risk localized disease
again suggested the benefit of this taxane [35]. The 4-year
overall survival favored patients treated with adjuvant
docetaxel after radiation, 93% vs. 89%, 1-sided p Z 0.03,
HR, 0.68. Furthermore, recent data comparing a new
taxane, cabazitaxel, with docetaxel in front line mCRPC
were unable to demonstrate that cabazitaxel was superior
to docetaxel [36]. These findings assure that docetaxel will
continue to be the premier chemotherapy in prostate
cancer for years to come.
There is a body of research that supports the use of
docetaxel in combination with immunotherapy which is
especially valuable in prostate cancer given the multiple
indications. Preclinical data have demonstrated that
docetaxel can enhance tumor associated antigen expression,
potentially increasing immune recognition of cancer cells.
Furthermore, docetaxel was able to increase FAS expression
on cancer cells, which is an important molecule whereby
immune cells can engage and kill cancer cells. In addition to
these findings, docetaxel has demonstrated to induce
antigen spreadingwhenusedwitha vaccine targeting a single
antigen, suggesting that immune combinations with
docetaxel could induce a broad immune response which
targets the cancer in a biologically diverse manner [37,38].
Therapeutic cancer vaccines have already been
combined with vaccines in several studies. Important data
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demonstrated that docetaxel given with vaccine did not
diminish the ability of the vaccine to induce an
antigen-specific immune response compared to vaccine
alone [39]. Another study in breast cancer with a pox viral
vaccine targeting MUC-1 and CEA demonstrated an increase
in progression free survival when vaccine was given with
docetaxel compared to docetaxel alone (median 7.9 vs 3.9
months, HR, 0.65, meeting prespecified statistical
requirements) [40]. In light of these findings, several
ongoing studies are combining vaccine with docetaxel in
both metastatic castration sensitive prostate cancer and
mCRPC (NCT02649855, NCT02111577, NCT02293707).
4.5. Combining immunotherapies
There is also a strong rationale to combine immunotherapies
with each other immune-based treatments. Preclinical data
have suggested that disparate therapeutic cancer vaccine
strategies can activate different immune cells, suggesting
that different immune approaches may stimulate different
aspects of the immune system [41]. In addition, there are
clinical data suggesting that vaccines could be combined
with immune checkpoint inhibitors such as ipilimumab. The
findings from these studies have taken on greater meaning
since phase 3 studies of ipilimumab in advance prostate
cancer did not demonstrate a clinical benefit (in terms of
overall survival) for ipilimumab alone [11].
One study combined ipilimumab with the whole tumor
cell vaccine GVAX. This study found that 7 of the 28 pa-
tients (25%) had a greater than 50% decline of PSA relative
to baseline, with stable disease ranging from 3 to 27 months
and one patient (of four with measurable disease) having
a complete response [42]. Another study combined
ipilimumab with the pox viral-based vaccine targeting PSA,
prostvac. In this trial, six of 30 patients had major PSA
declines greater than 50%, and the median overall survival
for all patients was 34.4 months (95%CI 29.6 to >41), with a
2-year benchmark overall survival analysis indicating 73% of
patients were still alive [43]. These findings are greater
than what has been reported with prostvac alone in terms
of overall survival and PSA responses, suggesting potential
synergy between these two agents.
To this point, prostate cancer is not been found to be
amenable to inhibitors that target the PD1/PD-L1 one axis.
Similarly, PD-L1 expression on prostate cancer tumors has
reported to be much lower than on other cancers. It is
possible that therapeutic cancer vaccines could help
stimulate immune cells in the periphery, driving them to
the tumor microenvironment as suggested by the
neoadjuvant study involving sipuleucel-T [9]. Interactions
that occur between immune cells in the tumor micro-
environment, perhaps mediated through the cytokine INFg,
may enhance PD-L1 expression and thereby potentiate such
therapies in patients or tumors those were generally
thought to be “PD-L1 negative” [44]. Several current clin-
ical trials are exploring this potential synergy in prostate
cancer. Additional future studies will investigate combining
immune platforms such as vaccines with immune
checkpoint inhibitors and other immune agents such as
(immuno)cytokines.5. Conclusion
Despite the fact that what could be considered the first
modern immunotherapy (sipuleucel-T) was approved for
the treatment of prostate cancer in 2010, subsequent
clinical development immunotherapy has largely occurred
outside of the field of prostate cancer research. With
several vaccines currently in late stages of clinical
development including prostvac, it is possible that there
may be more agents available in the near future. Combining
these agents together, with immune checkpoint inhibitors
and with standard therapeutics such as anti-androgens,
radiation, and chemotherapy, could yield superior clinical
outcomes. Several clinical trials are currently ongoing
investigating these types of immune combinations. If
proven efficacious, it may be rational to move these
therapies earlier on in the disease process, perhaps
including the adjutant or neoadjuvant setting. In
conjunction with definitive therapies such as surgery or
radiation-based therapy, future trials may explore if
immune-based platforms can increase the cure rate of
high-risk disease and perhaps even locally advanced or
minimally metastatic disease. Despite the recent
improvements in prostate cancer therapy, the journey of
the treatment development continues, with ongoing
immunotherapy trials helping to chart the course forward.
Conflicts of interest
The authors declare no conflict of interest.References
[1] Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ,
Penson DF, et al. Sipuleucel-T immunotherapy for castration-
resistant prostate cancer. N Engl J Med 2010;363:411e22.
[2] Madan RA, Gulley JL. Prospects for the future of prostate
cancer vaccines. Expert Rev Vaccines 2016;15:271e4.
[3] So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate
cancer. Expert Rev Anticancer Ther 2006;6:1163e7.
[4] Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP,
Kuan LY, et al. Sipuleucel-T immune parameters correlate
with survival: an analysis of the randomized phase 3 clinical
trials in men with castration-resistant prostate cancer. Cancer
Immunol Immunother 2013;62:137e47.
[5] George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.
Survival outcomes of sipuleucel-T phase III studies: impact of
control-arm cross-over to salvage immunotherapy. Cancer
Immunol Res 2015;3:1063e9.
[6] Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vac-
cines inprostate cancer: theparadoxof improved survivalwithout
changes in time to progression. Oncologist 2010;15:969e75.
[7] Small EJ, Schellhammer PF, Higano CS, Redfern CH,
Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III
trial of immunologic therapy with sipuleucel-T (APC8015) in
patients with metastatic, asymptomatic hormone refractory
prostate cancer. J Clin Oncol 2006;24:3089e94.
[8] Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA,
Haanen JB, et al. Improved survival with ipilimumab in patients
with metastatic melanoma. N Engl J Med 2010;363:711e23.
[9] Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J,
et al. Activated lymphocyte recruitment into the tumor
284 J.L. Gulley, R.A. Madanmicroenvironment following preoperative sipuleucel-T for
localized prostate cancer. J Natl Cancer Inst 2014;106.
[10] Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ,
Green JM, et al. CTLA-4 can function as a negative regulator
of T cell activation. Immunity 1994;1:405e13.
[11] Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den
Eertwegh AJ, et al. Ipilimumab versus placebo after radio-
therapy in patients with metastatic castration-resistant
prostate cancer that had progressed after docetaxel
chemotherapy (CA184-043): a multicentre, randomised,
double-blind, phase 3 trial. Lancet Oncol 2014;15:700e12.
[12] Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A,
Alumkal JJ, et al. Ipilimumab alone or in combination with
radiotherapy in metastatic castration-resistant prostate can-
cer: results from an open-label, multicenter phase I/II study.
Ann Oncol 2013;24:1813e21.
[13] Schellhammer PF, Chodak G,Whitmore JB, Sims R, Frohlich MW,
Kantoff PW. Lower baseline prostate-specific antigen is associ-
ated with a greater overall survival benefit from sipuleucel-T in
the immunotherapy for prostate adenocarcinoma treatment
(IMPACT) trial. Urology 2013;81:1297e302.
[14] Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP,
Skarupa L, et al. Immunologic and prognostic factors associ-
ated with overall survival employing a poxviral-based PSA
vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol Immunother 2010;59:663e74.
[15] Sharifi N, Gulley JL, Dahut WL. An update on androgen
deprivation therapy for prostate cancer. Endocr Relat Cancer
2010;17:R305e15.
[16] Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S,
et al. Androgen ablation mitigates tolerance to a prostate/-
prostate cancer-restricted antigen. Cancer Cell 2005;7:239e49.
[17] Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES,
Manecke RG, et al. T cell infiltration of the prostate induced
by androgen withdrawal in patients with prostate cancer. Proc
Natl Acad Sci USA 2001;98:14565e70.
[18] Williams KM, Lucas PJ, Bare CV, Wang J, Chu YW, Tayler E,
et al. CCL25 increases thymopoiesis after androgen with-
drawal. Blood 2008;112:3255e63.
[19] Madan RA, Hakim F, Jochems C, Heery CR, O’sullivan GC,
Singh H, et al. Impact of androgen deprivation therapy on the
thymus and the production of naı¨ve T-cells. J Immunother
Cancer 2013;1(Suppl 1):P83.
[20] Antonarakis ES, Kibel AS, Adams G, Krash LI, Elfiky A,
Shore ND, et al. A randomized phase II study evaluating the
optimal sequencing of sipuleucel-T and androgen deprivation
therapy in biochemically recurrent prostate cancer: immune
results. J Clin Oncol 2013;31. suppl; abstr 5016.
[21] Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC,
Frame JN, et al. Systemic therapy in men with metastatic
castration-resistant prostate cancer: American Society of
Clinical Oncology and Cancer Care Ontario clinical practice
guideline. J Clin Oncol 2014;32:3436e48.
[22] Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW.
Androgen deprivation therapy sensitizes prostate cancer cells
to T-cell killing through androgen receptor dependent modu-
lation of the apoptotic pathway. Oncotarget 2014;5:9335e48.
[23] Madan RA, Donahue RN, Singh H, Karzi F, Theoret MR,
Heery CR, et al. Clinical and immunologic impact of short
course enzalutamide without androgen deprivation therapy
for biochemically recurrent prostate cancer. J Clin Oncol
2016;34. suppl 2S; abstr 214.
[24] Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M,
Moros EG, Fishman M, et al. Abscopal benefits of localized
radiotherapy depend on activated T-cell trafficking and distribu-
tion between metastatic lesions. Cancer Res 2016;76:1009e18.
[25] Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J,
Kitano S, et al. Immunologic correlates of the abscopaleffect in a patient with melanoma. N Engl J Med 2012;366:
925e31.
[26] Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of
radiotherapy: new paradigms. Radiat Res 2014;182:123e5.
[27] Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiation-induced
survival responses promote immunogenic modulation to
enhance immunotherapy in combinatorial regimens. Oncoim-
munology 2014;3:e28643.
[28] Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P,
et al. Combining a recombinant cancer vaccine with standard
definitive radiotherapy in patients with localized prostate
cancer. Clin Cancer Res 2005;11:3353e62.
[29] Heery CR, Madan RA, Stein MN, Stadler WM, Dipaola RS.
Samarium-153-EDTMP (Quadramet) with or without vaccine in
metastatic castration-resistant prostate cancer: a randomized
phase 2 trial. OncoTarget 2016. http://dx.doi.org/10.18632/
oncotarget.10883 [Epub ahead of print].
[30] Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE,
et al. Samarium-153-Lexidronam complex for treatment of
painful bone metastases in hormone-refractory prostate can-
cer. Urology 2004;63:940e5.
[31] Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM,
Fossa˚ SD, et al. Alpha emitter radium-223 and survival in
metastatic prostate cancer. N Engl J Med 2013;369:213e23.
[32] Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN,
et al. Docetaxel plus prednisone or mitoxantrone plus pred-
nisone for advanced prostate cancer. N Engl J Med 2004;351:
1502e12.
[33] Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA,
Taplin ME, et al. Docetaxel and estramustine compared with
mitoxantrone and prednisone for advanced refractory pros-
tate cancer. N Engl J Med 2004;351:1513e20.
[34] Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF,
Eisenberger M, et al. Chemohormonal therapy in metastatic
hormone-sensitive prostate cancer. N Engl J Med 2015;373:
737e46.
[35] Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomella LG,
Amin M, et al. A phase III protocol of androgen suppression
(AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by
chemotherapy with docetaxel and prednisone for localized,
high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33.
suppl; abstr LBA5002.
[36] Sartor O. Cabazitaxel vs. docetaxel in chemotherapy-naive
(CN) patients with metastatic castration-resistant prostate
cancer. ASCO Annu Meet Abstr 2016.
[37] Garnett CT, Schlom J, Hodge JW. Combination of docetaxel
and recombinant vaccine enhances T-cell responses and
antitumor activity: effects of docetaxel on immune
enhancement. Clin Cancer Res 2008;14:3536e44.
[38] Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY,
Ferrone S, et al. Chemotherapy-induced immunogenic modu-
lation of tumor cells enhances killing by cytotoxic T lympho-
cytes and is distinct from immunogenic cell death. Int J
Cancer 2013;133:624e36.
[39] Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D,
et al. A randomized phase II study of concurrent docetaxel plus
vaccine versus vaccine alone in metastatic androgen-
independent prostate cancer. Clin Cancer Res 2006;12:1260e9.
[40] Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL,
Koenig K, et al. Docetaxel alone or in combination with a
therapeutic cancer vaccine (PANVAC) in patients with meta-
static breast cancer: a randomized clinical trial. JAMA Oncol
2015;1:1087e95.
[41] Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW.
Concurrent vaccination with two distinct vaccine platforms
targeting the same antigen generates phenotypically and
functionally distinct T-cell populations. Cancer Immunol
Immunother 2010;59:397e408.
Immunotherapy strategies in prostate cancer 285[42] van den Eertwegh AJ, Versluis J, van den Berg HP,
Santegoets SJ, van Moorselaar RJ, van der Sluis TM,
et al. Combined immunotherapy with granulocyte-
macrophage colony-stimulating factor-transduced alloge-
neic prostate cancer cells and ipilimumab in patients
with metastatic castration-resistant prostate cancer: a
phase 1 dose-escalation trial. Lancet Oncol 2012;13:
509e17.[43] Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M,
Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting
prostate-specific antigen in metastatic castration-resistant pros-
tate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:
501e8.
[44] Strauss J, Madan RA, Gulley JL. Considerations for the com-
bination of anticancer vaccines and immune checkpoint in-
hibitors. Expert Opin Biol Ther 2016;16:895e901.
